| Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis -> Monitor Keywords |
|
Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesisUSPTO Application #: 20060223761Title: Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis Abstract: Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease Also disclosed pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions. (end of abstract)
Agent: Buchanan, Ingersoll & Rooney PC - Alexandria, VA, US Inventors: James E. Audia, Thomas C. Britton, James J. Droste, Beverly K. Folmer, George W. Huffman, Varghese John, Lee H. Latimer, Thomas E. Mabry, Jeffrey S. Nissen, Warren J. Porter, Jon K. Reel, Eugene D. Thorsett, Jay S. Tung, Jing Wu, Clark Norman Eid, William Leonard Scott USPTO Applicaton #: 20060223761 - Class: 514019000 (USPTO) Related Patent Categories: Drug, Bio-affecting And Body Treating Compositions, Designated Organic Active Ingredient Containing (doai), Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai, Cyclopeptides, 2 Peptide Repeating Units In Known Peptide Chain The Patent Description & Claims data below is from USPTO Patent Application 20060223761. Brief Patent Description - Full Patent Description - Patent Application Claims CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application claims the benefit of the following U.S. Provisional Applications: [0002] 1. U.S. Provisional Application No. 60/______ which was converted pursuant to 37 C.F.R. .sctn.1.53(b)(2)(ii) from U.S. patent application Ser. No. 08/755,442, filed Nov. 22, 1996; [0003] 2. U.S. Provisional Application No. 60/______ which was converted pursuant to 37 C.F.R. .sctn.1.53(b)(2)(ii) from U.S. patent application Ser. No. 08/808,528, filed Feb. 28, 1997; [0004] 3. U.S. Provisional Application No. 60/______ which was converted pursuant to 37 C.F.R. .sctn.1.53(b)(2)(ii) from U.S. patent application Ser. No. 08/807,528, filed Feb. 28, 1997; and [0005] 4. U.S. Provisional Application No. 60/______ which was converted pursuant to 37 C.F.R. .sctn.1.53(b)(2)(ii) from U.S. patent application Ser. No. 08/807,427, filed Feb. 28, 1997. [0006] Each of these applications are incorporated herein by reference in their entirety. BACKGROUND OF THE INVENTION Field of the Invention [0007] This invention relates to methods which inhibit cellular .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. This invention also relates to pharmaceutical compositions comprising such compounds as well as methods for inhibiting release of .beta.-amyloid peptide. REFERENCES [0008] The following publications, patents and patent applications are cited in this application as superscript numbers: [0009] .sup.1Glenner, et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", Biochem. Biophys. Res. Commun., 120:885-890 (1984). [0010] .sup.2 Glenner, et al., "Polypeptide Marker for Alzheimer's Disease and its Use for Diagnosis", U.S. Pat. No. 4,666,829 issued May 19, 1987. [0011] .sup.3 Selkoe, "The Molecular Pathology of Alzheimer's Disease", Neuron, 6:487-498 (1991). [0012] .sup.4 Goate, et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", Nature, 349:704-706 (1990). [0013] .sup.5 Chartier-Harlan, et al., "Early-Onset Alzheimer's Disease Caused by Mutations at Codon 717 of the .beta.-Amyloid Precursor Protein Gene", Nature, 353:844-846 (1989). [0014] .sup.6 Murrell, et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease", Science, 254:97-99 (1991). [0015] .sup.7 Mullan, et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of .beta.-Amyloid, Nature Genet., 1:345-347 (1992). [0016] .sup.8 Schenk, et al., "Methods and Compositions for the Detection of Soluble .beta.-Amyloid Peptide", International Patent Application Publication No. WO 94/10569, published 11 May 1994. [0017] .sup.9 Selkoe, "Amyloid Protein and Alzheimer's Disease", Scientific American, pp. 2-8, November, 1991. [0018] .sup.10 Losse, et al., Tetrahedron, 27:1423-1434 (1971). [0019] .sup.11 Citron, et al., "Mutation of the .beta.-Amyloid Precursor Protein in Familial Alzheimer's Disease Increases .beta.-Protein Production, Nature, 360:672-674.(1992). [0020] .sup.12 Hansen, et al., "Reexamination and Further Development of a Precise and Rapid Dye Method for Measuring Cell Growth/Cell Kill", J. Immun. Meth., 119:203-210 (1989). Continue reading... Full patent description for Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis patent application. ### 1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis or other areas of interest. ### Previous Patent Application: Substituted 1,2-ethylenediamines, methods for preparing them and uses thereof Next Patent Application: C-glycoside compounds for stimulating the synthesis of glycosaminoglycans Industry Class: Drug, bio-affecting and body treating compositions ### FreshPatents.com Support Thank you for viewing the Methods and compounds for inhibiting beta-amyloid peptide release and/or its synthesis patent info. IP-related news and info Results in 1.12498 seconds Other interesting Feshpatents.com categories: Novartis , Pfizer , Philips , Polaroid , Procter & Gamble , |
||